Business Context and Reporting Period
This Form 8-K is a current report filed by TScan Therapeutics, Inc. (TCRX) on September 8, 2026. The filing discloses the approval of a key employee retention program by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes and Compensation Details
The Board approved a Retention Program for key employees, specifically CEO Gavin MacBeath, Ph.D., and Chief Legal and Strategy Officer Zoran Zdraveski, JD, Ph.D. The program includes:
- Cash Awards:
- Dr. MacBeath: $822,000 total.
- Dr. Zdraveski: $416,000 total.
- Payout Structure: One-third of the first half of the award is payable in November 2026; the remaining two-thirds of the first half is payable in February 2027. The second half of the award is contingent upon achieving a "Clinical Milestone" related to the advancement of the Company's in vivo solid tumor program.
- Equity Awards (RSUs):
- Dr. MacBeath: 2,400,000 Restricted Stock Units (RSUs).
- Dr. Zdraveski: 1,050,000 RSUs.
- Vesting Structure: One-third vests upon achieving a "Financing Milestone." The remaining two-thirds vest in equal installments on the first and second anniversaries of the Financing Milestone, subject to continued service.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the Retention Program and the Company's future expectations. Management highlights substantial risks and uncertainties, noting that actual results may differ significantly from expectations. Specific contingencies include the achievement of the Clinical Milestone for cash payouts and the Financing Milestone for equity vesting. The Company disclaims any obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the specific definitions of the "Clinical Milestone" and "Financing Milestone" in the underlying award agreements.
- Confirm the Company's current cash position to assess the ability to fund the November 2026 and February 2027 cash payments.
- Review the 2021 Equity Incentive Plan to understand the dilution impact of the 3,450,000 total RSUs granted.
- Monitor subsequent filings for updates on the status of the in vivo solid tumor program and financing activities.